Business
Schrödinger to Participate in Five Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are
About this update from Schrodinger, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nSchrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate virtually at the following investor conferences:\n\n\n33rd Annual Piper Sandler Virtual Healthcare Conference: A pre-recorded fireside chat will be available today after 10:00 a.m. ET.\n\n\n4th Annual Evercore ISI HealthCONx Conference: Management will participate in a fireside chat on Tuesday, November 30, 2021, at 4:20 p.m. ET.\n\n\nBMO 2021 Growth & ESG Conference: A fireside chat will take place on Tuesday, December 7th at 1:00 p.m. ET.\n\n\nGoldman Sachs Byte-ology: The Convergence of Biotechnology and Technology: A Biotech panel will take place on Thursday, December 9, 2021, at 10:00 a.m. ET.\n\n\nAdditionally, the company will participate in one-on-one meetings during the Berenberg Discover AI Seminar 2021 on Wednesday, December 1st.\n\nThe live and pre-recorded webcasts can be accessed under \"News & Events\" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.\n\nAbout Schrödinger\n\nSchrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.\n\nFounded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, our blog www.extrapolations.com, or follow us on LinkedIn and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211122005950/en/\n\nJaren Irene Madden\nSchrödinger, Inc.\[email protected]\n617-286-6264\n\nTracy Lessor\nSchrödinger, Inc.\[email protected]\n...